Related Experiment Videos

[Betaxolol treatment of hypertension in postmenopausal women]

M M Bystrova, A N Britov, V M Gorbunov

    Terapevticheskii Arkhiv
    |July 27, 1999
    PubMed
    Abstract

    Insights

    High-cardioselective beta-blocker betaxolol effectively lowers blood pressure in women with hypertension. It also improves menopausal symptoms without negatively impacting lipid or carbohydrate metabolism.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Women's Health

    Background:

    • Arterial hypertension is a prevalent condition in postmenopausal women.
    • Managing hypertension requires careful consideration of metabolic and menopausal side effects.

    Purpose of the Study:

    • To evaluate the hypotensive efficacy of the high-cardioselective beta-blocker betaxolol.
    • To assess betaxolol's effects on lipid and carbohydrate metabolism.
    • To determine the impact of betaxolol on menopausal syndrome in hypertensive women.

    Main Methods:

    • A trial involving 20 postmenopausal women (45-59 years) with mild to moderate hypertension.
    • Evaluation of arterial pressure, heart rate, body mass, lipid profile, glucose, and insulin levels.
    • Measurements taken before and at 1, 3, and 6 months after betaxolol treatment.

    Main Results:

    • Betaxolol demonstrated safe and effective blood pressure reduction.
    • No significant changes were observed in the blood lipid spectrum.
    • A transient increase in fasting insulin levels did not impair glucose tolerance, despite minor weight gain.
    • Significant relief of menopausal symptoms, particularly vasomotor disorders, was noted.

    Conclusions:

    • Betaxolol offers a beneficial hypotensive effect for hypertensive postmenopausal women.
    • The drug exhibits a favorable metabolic profile, with no adverse effects on lipid or carbohydrate metabolism.
    • Betaxolol effectively alleviates menopausal syndrome, improving overall quality of life.

    Related Concept Videos

    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...